Announcement • Jun 04
Light AI Initiates FDA Pivotal Clinical Trial for QuickScan Strep a Software as a Medical Device Light AI Inc. has received ethics committee approval to commence the pivotal clinical trial intended to generate clinical evidence to support a future submission to the U.S. Food and Drug Administration for potential marketing authorization of QuickScan Strep A as a Class II medical device. The study protocol and design are informed by prior regulatory interactions, including pre-submission feedback received by the Company during its 2024 FDA Q-Sub process. QuickScan Strep A is being developed as a smartphone-enabled software platform intended to analyze throat images and provide an AI-supported assessment for suspected Strep A infection. The software remains investigational and has not been cleared or approved by the FDA or other regulatory authorities for commercial diagnostic use. The pivotal study is expected to enroll participants presenting with symptoms consistent with pharyngitis and is designed to compare the diagnostic performance of QuickScan Strep A against throat culture, an established clinical reference standard. Predefined study endpoints include diagnostic outcome measures, usability assessments, and patient management-related measures intended to support evaluation of software performance and a future FDA submission. Strep A pharyngitis is a common condition evaluated across primary care, urgent care, pediatric, pharmacy and community healthcare settings. Subject to successful clinical validation, regulatory authorization and commercial adoption, Light AI believes there may be future opportunities for software-enabled assessment technologies to support healthcare delivery and patient management pathways. The Company expects to provide updates regarding study progress, enrollment milestones, and timing considerations as appropriate and in accordance with applicable securities disclosure obligations. Announcement • Jun 02
Light AI Inc., Annual General Meeting, Jul 22, 2026 Light AI Inc., Annual General Meeting, Jul 22, 2026. Location: british columbia, vancouver Canada Announcement • May 22
Light AI Inc. announced that it expects to receive CAD 5 million in funding Light AI Inc. announced a private placement with MV Capital LP to issue 5,000 secured convertible debenture units at an issue price of CAD 1,000 for the proceeds of CAD 5,000,000 on May 21, 2026. Each Unit will comprise of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to CAD 1,000 (each, a "Convertible Debenture") with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or conversion and maturing 24 months from the closing of the Financing (the "Maturity Date"), and (ii) 8,000 common share purchase warrants (each, a "Warrant"), each Warrant being exercisable for a period of 36 months following the closing of the Financing (the "Closing Date") to purchase one common share of the Company (each, a "Warrant Share") at an exercise price of CAD 0.25 per Warrant Share. The Financing is expected to close on or around June 19, 2026, and is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Exchange. 
